Effect of beraprost sodium on pulmonary vascular resistance in candidates for a Fontan procedure: A preliminary study

Pediatrics International

Volumn 45, Issue 6, 2003, Pages 671-675

  Takahashi, Kazuhiro ^a   Mori, Yoshiki ^a   Yamamura, Hideshi ^a   Nakanishi, Toshio ^a   Nakazawa, Makoto ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Beraprost sodium; Congenital heart defect; Fontan procedure; Pulmonary hypertension

Indexed keywords

BERAPROST;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FONTAN PROCEDURE; HEART CATHETER; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SYSTEMIC CIRCULATION; TREATMENT FAILURE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EPOPROSTENOL; FEMALE; FONTAN PROCEDURE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; MALE; PULMONARY CIRCULATION; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 1642562703     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2003.01800.x     Document Type: Article

References (24)

1. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. 1998; 338: 273-7.
2. Nagaya N, Uematsu M, Okano Y et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J. Am. Coll. Cardiol. 1999; 34: 1188-92.
3. Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 2002; 39: 1496-502.
4. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-65.
5. Suzuki H, Sato S, Tanabe S, Hayakawa K. Beraprost sodium for pulmonary hypertension with congenital heart disease. Pediatr. Int. 2002; 44: 528-9.
6. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 1996; 334: 296-301.
7. Thomas LG, John EM, Kimberlee G et al. Fontan operation in five hundred consecutive patients: Factors influencing early and late outcome. J. Thorac. Cardiovasc. Surg. 1997; 114: 376-91.
8. Masuda M, Kado H, Shiokawa Y et al. Clinical results of the staged Fontan procedure in high-risk patients. Ann. Thorac. Surg. 1998; 65: 1721-5.
9. Mayer JE, Helgason H, Jonas RA et al. Extending the limits for modified Fontan procedures. J. Thorac. Cardiovasc. Surg. 1986; 92: 1021-8.
10. Kaulittz R, Ziemer G, Luhmer I, Kallfelz HC. Modified Fontan operation in functionally univentricular hearts: Preoperative risk factors and intermediate results. J. Thorac. Cardiovasc. Surg. 1996; 112: 658-64.
11. Park I, Nakazawa M, Imai Y, Sawatari K, Momma K. Prediction of quality of life at long-term follow-up after Fontan operation by scoring risk factors. Jpn. Circ. J. 1994; 58: 646-52.
12. La Farge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc. Res. 1970; 4: 23-30.
13. Grossman W. Cardiac Catheterization and Angiography, 3rd edn. Lea & Febiger, Philadelphia, 1986.
14. Nakata S, Imai Y, Takanashi Y et al. A new method for the quantitative standardization of cross-sectional areas of the pulmonary arteries in congenital heart diseases with decreased pulmonary blood flow. J. Thorac. Cardiovasc. Surg. 1984; 88: 610-19.
15. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol. Pharmacol. 1995; 48: 890-96.
16. John W, Neil D, Paul DP et al. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000; 102: 3130-36.
17. Sakamaki F, Kyotani S, Nagaya N et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102: 2720-25.
18. Rich S, ed. Executive summary. In: The World Symposium on Primary Pulmonary Hypertension 1998; September 6-10, 1998, Evian, France, Co-Sponsored by the World Health Organization.
19. Gaynor JW, Collins MH, Rychik J, Guaghan JP, Spray TL. Long-term outcome of infants with single ventricle and anomalous pulmonary venous connection. J. Thorac. Cardiovasc. Surg. 1999; 117: 506-14.
20. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease. Circulation 1958; 18: 533-47.
21. Robert LG, John Jr EM, Ruthellen F et al. Role of lung biopsy in patients undergoing a modified Fontan procedure. J. Thorac. Cardiovasc. Surg. 1990; 99: 451-9.
22. Yamaki S, Ajiki H, Takanashi Y, Ban T, Takanashi T. Pulmonary arterial changes in the patients dying after modified Fontan operation. Heart Vessels 1994; 9: 263-8.
23. Levy M, Danel C, Tamisier D, Vouhe P, Leca F. Histomorphometric analysis of pulmonary vessels in single ventricle for better selection of patients for the Fontan operation. J. Thorac. Cardiovasc. Surg. 2002; 123: 263-70.
24. Rabinovitch M, Castaneda AR, Reido LM. Lung biopsy with frozen section as a diagnostic aid in patients with congenital heart defect. Am. J. Cardiol. 1981; 47: 77-84.